Market Signal Briefing

A wallet allegedly linked to the world’s largest YouTuber, MrBeast, has accumulated over $1 million worth of BNB Chain-based decentralized exchange token ASTER over the past few days.

Summary

A wallet allegedly tied to MrBeast accumulated over $1 million worth of ASTER, according to Lookonchain.
ASTER has surged more than 1,800% since launch.

According to the on-chain analytics platform Lookonchain, the latest transaction is one of many that the YouTuber has reportedly conducted through wallets attributed to him.

Alleged MrBeast linked wallet buys Aster token | Source: Lookonchain
A few hours before Lookonchain’s Sep. 29 update, this wallet transferred 320,587 USDT to purchase 167,436 ASTER tokens, pushing the cumulative total to 705,821 ASTER, roughly $1.28 million at acquisition.

These purchases come on the heels of earlier reports by Lookonchain from Sep. 26, where it was noted that the same wallet had accumulated 538,384 ASTER tokens (worth around $990,000 at the time) over three days, with an average entry price estimated at $1.87 per token.

At the time, 1 million USDT was deposited using two wallets, 0x9e67, which is publicly associated with MrBeast, and 0x0e8A, a newly created address.

The first reported transaction tracked by Lookonchain took place on September 21, when the YouTuber’s public wallet sent 114,483 USDT to Aster, marking what appears to be the start of this accumulation spree. (See below.)

Alleged MrBeast linked wallet buys Aster token | Source: Lookonchain
Although blockchain data clearly links the transactions to wallets previously associated with MrBeast, the YouTuber himself has publicly denied any involvement. Replying to one X user on Sep. 22, MrBeast said he had “never heard of that coin” and insisted that the wallet identified by 0x9e67 was not his and warned followers not to be misled by anyone pretending to act on his behalf.

MrBeast denies investing in ASTER | Source: MrBeast on X
However, the speculation around the YouTuber’s involvement with ASTER didnot translate into any major price swings, with the token up a little over 3% at press time, trading it $1.92.

Aster skyrocets post launch
Since its launch on Sep. 17, the ASTER token has rallied over 1800% in less than two weeks to hit an all-time high of $2.41. 

Much of the hype around the token stems from support from industry heavyweights like former Binance CEO Changpeng Zhao, who has hinted at plans to contribute to the decentralized ecosystem, and the role of Aster as a leading decentralized perpetual exchange.

Aster has also managed to dethrone its top competitors, including Hyperliquid and Lighter, in both revenue and trading volume. At the time of writing, it ranked as the number one perpetual DEX by 24-hour volume at $42.88 billion, compared to Lighter’s just $5.75 billion, its closest rival.

This rapid rise to fame has managed to trigger noticeable whale activity around the token. Data from Nansen indicates that the total amount of ASTER held by whales has jumped from 10.1 million to 72.76 million over the past 7 days.

ASTER tokens held across whale wallets | Source: Nansen

U.S. spot Bitcoin exchange-traded funds (ETFs) posted their first week of outflows in more than a month as quarter-end rebalancing and profit-taking weighed on institutional activity. While the setback has raised questions, analysts say the long-term outlook for institutional adoption remains firm.

According to reporting by The Big Whale, the network is working with more than a dozen global banks, including BNP Paribas and BNY Mellon, to test how its secure messaging system could run on Linea, an Ethereum Layer 2 built by Consensys. The project is still under development.

Capital B (The Blockchain Group, ISIN: FR0011053636, ticker: ALCPB) has completed an “ATM‑type” capital increase with TOBAM at €1.70 per share, raising €1.2 million ($1.4 million) to acquire 12 BTC. The transaction brings the group's total crypto treasury to 2,812 BTC, acquired for €262.1 million ($307.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

The Pi Network leadership team is facing some tough questions over the utility of Pi coin and other developments, as the native cryptocurrency slips out of the top 50 crypto list. With a 22% correction over the past week, the altcoin is now finding a base at $0.25. Experts are now questioning the silence of the Pi Core team behind the delays in mainnet launch, the misuse of $20 million in funding, and much more.

Pi Network Team Allegedly Misused $20 Million in Funds
The Pi Network is under renewed scrutiny following allegations from former executive McPhilip, who claims he was unfairly removed from the project while its financial resources were mishandled. Court filings, dating back to 2020, reveal internal disputes between co-founders Dr. Nicolas Kokkalis and Chengdiao Fan, allegedly creating a toxic workplace. Fan will reportedly be speaking at the TOKEN2049 event this week, happening on October 1-2.

McPhilip further alleges that the co-founders attempted to dilute his ownership by issuing new shares at $0.00005 each. This happened despite earlier fundraising in 2019–2020, valuing the company at $20 million. He also claims his access to company servers, financial accounts, and operational tools was revoked after internal conflicts escalated.

The Pi community members have started questioning developers over their failure to create a Pi Network ecosystem. This has eventually left the Pi coin having no utility in the first place. Popular Pi Community member Mr. Spock wrote:

“The Core Team received $20 million in funding in 2019. They could have built the entire ecosystem with 100 apps back in 2020 with all that funding, yet they hid it from us and investors. The whole time, they had the funding to build Pi Network the right way, but there was conflict over control and personal issues from the founders”.

These disputes explain the Pi Core Team’s lack of communication with its large user base. It has further raised questions about transparency, governance, and whether leadership struggles have undermined the project’s “community-first” vision. As the Core team remains silent on key issues, the sentiment within the Pi Community is waning despite recent developments of getting Protocol v23 on testnet.

Pi Coin Slips Out of Top 50 Crypto List
Last week, the Pi coin price tanked by 25% slipping all the way to the support levels at $0.25. Amid this downfall, the altcoin has slipped out of the list of top 50 crypto assets, despite ongoing rumors of Binance listing.

Earlier this year, Pi coin grabbed a spot among the top 15 crypto assets, however, continuous delays in mainnet launch and failure to come up with a concrete plan by the Pi core team have led to huge sell-offs. Furthermore, the Core team has continued to maintain the anomaly with respect to the Global Consensus Value (GCV), which pegs each Pi coin at $314,159, much above the current trading price of $0.26. This lack of clarity has led supporters to lose trust in the project.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

Active Currencies 18882

Market Cap $3,885,012,683,026.60

Bitcoin Share 56.41%

24h Market Cap Change $0.75

AMBCrypto

Hyperliquid’s Hypurr NFT airdrop backfires – $400K hack sparks jitters

Posted: September 29, 2025

Key Takeaways
What are Hypurr NFTs, and who received them?
Hypurr NFTs are unique digital collectibles airdropped to early Hyperliquid users as a reward for supporting the project.

Are there any risks following the Hypurr NFT drop?
Yes, several NFTs tied to compromised wallets were stolen, and analysts are wary of a looming $12B HYPE token unlock that could impact prices.

Early users of Hyperliquid [HYPE] just got a big reward for sticking around.

On the 28th of September, the Hyper Foundation rolled out its long-awaited Hypurr NFT collection, handing out these digital collectibles to early adopters of the perpetuals-focused Layer-1 blockchain.

Hypurr NTFs arrive with security concerns

Samyukhtha L KM is a Financial Journalist and Market Analyst at AMBCrypto whose work is defined by one central question: Is the latest trend in blockchain hype, or history in the making?
Her expertise is built on a strong academic foundation, with a Master’s in Journalism and Mass Communication from Amity University and a Bachelor’s in Commerce from the University of Madras. This dual qualification equips her with a unique skill set: the financial acumen to dissect market mechanics and the journalistic rigor to investigate and communicate complex subjects with clarity.
Samyukhtha specializes in analyzing the socio-economic impact of blockchain adoption and assessing the viability of new market narratives. This includes a focus on high-velocity, community-driven assets such as memecoins, where she evaluates sentiment and fundamentals. She is dedicated to providing readers with insightful, well-researched commentary that looks beyond immediate market moves to understand the long-term implications of decentralized technology.

Top crypto commentator CryptoinsightUK argues that market consensus has misread the setup for XRP and altcoins, contending that sentiment, liquidity positioning, and cross-asset relationships point to an imminent phase in which XRP could outperform even a resurgent ETH.

In his latest Weekly Insight (Week 161, Sept. 27, 2025), the analyst opens with a blunt reset of stance: “I am bullish.” He acknowledges the psychological toll of recent chop and public pushback—“I am getting pushback from all sides for staying bullish… But I also do not really care”—yet he frames the current drawdown as the kind of fear-laced inflection that historically precedes a trend resumption higher.

Why Is Everyone Wrong About XRP?
The note situates the call against a noisy backdrop. He cites well-followed traders who either called a top or de-risked into weakness, and the victory laps of dominance-maxi voices after a bounce in Bitcoin dominance. The riposte is data-driven: sentiment gauges near “fear” readings of 40 or below, a zone that has repeatedly coincided with local lows or pre-reversal conditions. While he concedes that “we could see a slight further correction,” the weight of evidence, he argues, skews to upside.

A key pillar is liquidity mapping. On Bitcoin, he highlights sizeable resting liquidity around $106,000—a pool that has persisted since mid-July and remains uncollected despite spot advances as high as $123,000. “I would expect this 106k area of liquidity to be taken, maybe even down to 104k with a wick,” he writes, emphasizing that a tag into that zone would not invalidate the higher-timeframe bull structure.

Bitcoin liquidity | Source: @CryptoinsightUK
Crucially, he says, the “largest amount of liquidity ever” sits above price, implying that if a major top were in, “market makers… would [not] allow that much liquidity to remain untouched.” By contrast, lower-side liquidity down around $70,000 is drying up, suggesting reduced gravitational pull to the downside as stale longs and shorts have been flushed or realized.

That skew, he says, is even more pronounced across majors and large-cap alts. On daily time frames for ETH, Cardano, XRP, and SUI, “significant liquidity” has rebuilt above spot, while “minor” pockets remain below—an asymmetry that makes precise dip-buy levels hard to pre-declare yet keeps the “ultimate outcome” biased to a leg higher.

The timing cue rests on two oscillators that often mark rotation windows: ETH is now as oversold on the 4-hour as it was at the exact cycle bottom around $1,400—a setup not seen again during its run toward $5,000—while Bitcoin Dominance (BTC.D) has reached overbought on the 4-hour. “The last three times this happened, it marked either a local high, the exact high, or came just before a larger drawdown in Bitcoin Dominance,” he notes.

On the weekly, he expects the structural outcome to be an acceleration lower in dominance later in the cycle, and he leaves open whether that moment is now. The mosaic—ETH deeply oversold, BTC.D heavily overbought, liquidity stacked above alts—supports his conclusion that “very soon it is likely to be the altcoin show.”

Bitcoin dominance | Source: @CryptoinsightUK
Within that rotation, XRP vs. ETH is his sharpest edge. On the 4-hour XRP/ETH chart, he sees a local bottom structure—“a series of lows, higher lows, and higher highs”—with a trigger level at 0.00071 ETH per XRP: “We are looking for closes above the 0.00071 level, and the larger the timeframe of the close above that level, the greater the likelihood of reversal.”

XRP vs. ETH | Source: @CryptoinsightUK
On the weekly XRP/ETH, he sketches two Elliott-wave roadmaps: a conservative five-wave path back to the prior highs against ETH, and a higher-beta alternative that starts from the candle structure shift and implies “exponential growth” in relative terms this cycle. The combined thesis is explicit: “ETH looks poised to perform well… [and] XRP looks ready to outperform ETH on top of that. Use your imagination for what could happen if those two things play out together.”

At press time, XRP traded at $2.86.

XRP price, 1-day chart | Source: XRPUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

By Reuters

September 29, 20256:10 AM UTCUpdated ago

Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo Purchase Licensing Rights, opens new tab

CompaniesSept 29 (Reuters) - British drugmaker GSK

(GSK.L), opens new tab said on Monday Emma Walmsley will step down as CEO after nine years at the helm and will be replaced by insider Luke Miels.

Miels, who joined GSK in 2017, is currently the drugmaker's chief commercial officer. He will assume full responsibilities as chief executive on January 1.

Sign up here.

""2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership," Walmsley said.

Reporting by Yadarisa Shabong in Bengaluru; Editing by Mrigank Dhaniwala

Our Standards: The Thomson Reuters Trust Principles., opens new tab

By Reuters

September 29, 20256:10 AM UTCUpdated ago

The TotalEnergies logo sits on the company's headquarters skyscraper in the La Defense business district near Paris, France, June 26, 2023. REUTERS/Stephanie Lecocq/File Photo Purchase Licensing Rights, opens new tab

CompaniesSept 29 (Reuters) - TotalEnergies

(TTEF.PA), opens new tab will sell 50% of a solar portfolio in North America to KKR

(KKR.N), opens new tab, the energy group said on Monday.

The group said in a statement it will receive a total of $950 million for the sale.

Sign up here.

Reporting by Alessandro Parodi; Editing by Matt Scuffham

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Toyota Motor Corp reported Monday that its global vehicle sales rose for an eighth consecutive month in August, supported by strong demand for hybrid models in the United States despite weaker domestic performance. Worldwide sales increased 2.2 percent year-on-year to 844,963 vehicles, with US sales climbing 13.6 percent.

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept. 29.

Analysts expect the Daix, France-based company to report H1 loss at 41 cents per share. Inventiva projects quarterly revenue of $5.31 million, according to data from Benzinga Pro.

Inventiva is scheduled to host Analyst and Investor Event on Oct. 8.

Shares of Inventiva rose 0.7% to close at $6.05 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

HC Wainwright & Co. analyst Ananda Ghosh assumed coverage on the stock with a Buy rating and a price target of $20 on Sept. 3, 2025. This analyst has an accuracy rate of 61%.
Guggenheim analyst Etzer Darout maintained a Buy rating and boosted the price target from $9 to $13 on Sept. 2, 2025. This analyst has an accuracy rate of 54%.
Piper Sandler analyst Yasmeen Rahimi initiated coverage on the stock with an Overweight rating and a price target of $26 on Aug. 27, 2025. This analyst has an accuracy rate of 66%.
Stifel analyst Annabel Samimy maintained a Buy rating and cut the price target from $20 to $17 on Nov. 22, 2024. This analyst has an accuracy rate of 66%.
UBS analyst Eliana Merle initiated coverage on the stock with a Neutral rating and a price target of $3 on Nov. 12, 2024. This analyst has an accuracy rate of 53%
Considering buying IVA stock? Here’s what analysts think:

Read This Next:

How To Earn $500 A Month From Lamb Weston Stock Ahead Of Q1 Earnings
Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Daix (France), New York City (New York, United States), September 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial results for the six months ended June 30, 2025, and provided a corporate update. Frédéric Cren, Chief Executive Officer and cofounder of Inventiva, stated: “ The first half of 2025 has been a defining period for Inventiva, with decisive progress across both our clinical program and our financial position. As we advance into the final stretch of our Phase 3 clinical trial in MASH, we are reinforcing our organization to prepare for the upcoming data readouts and potential regulatory submissions. Financially, we reinforced our position with the closing of the €116 million second tranche of the structured financing announced in October 2024, unlocked by the randomization of the last patient in the main cohort of the NATiV3 study, a critical milestone in our journey. Inventiva has entered the second half of the year with confidence and undiminished ambition: to turn the hope of millions of patients living with MASH into therapeutic reality. ”

GSK PLC (LSE:GSK, NYSE:GSK) chief executive Dame Emma Walmsley will step down at the end of December this year after almost nine years in the role. 

The pharmaceutical group has promoted its chief commercial officer, Luke Miels, as CEO designate from today, and he will take on the full CEO role from 1 January 2026. 

The Australian joined the FTSE 100 company in 2017, the year that Walmsley became CEO, and in his current role he is responsible for the FTSE 100 company's portfolio of medicines and vaccines.

He joined from AstraZeneca, where he was executive vice president of their European business and, before that, was head of global product and portfolio strategy, global medical affairs and corporate affairs. Prior to that he was head of Asia for Roche, based in Shanghai and Singapore.

Chair Sir Jonathan Symonds hailed Walmsley's "outstanding leadership in delivering a strategic transformation of GSK, including the successful demerger of Haleon".

He said Miels "has outstanding global biopharma development and commercial experience, together with a deep understanding of the company, its prospects and its people. He is extremely well placed to lead, deliver and surpass the ambitions we have set for GSK, and to generate new growth and value for patients and shareholders."

For her part, Walmsley said: "2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership."

She will step down from the board on 31 December 2025, but will remain with the business until her notice period ends on 30 September 2026.

The company said she will "support an orderly transition throughout that period" and "given the potential impact to GSK's operating environment arising from geopolitics and new technologies, the board has asked Emma to support the company and the new CEO on these matters". 

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BCRX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

David Tepper Nails China TradeAppaloosa Management’s David Tepper is a generational talent and one of the most successful investors of all time. Tepper has amassed a multi-billion-dollar fortune and accrued so much wealth that he was able to purchase the Carolina Panthers NFL team. How did Tepper become so wealthy? Tepper has made his fortune with an investing technique that bets against the crowd, takes high-conviction bets, and places large bets. For instance, in the fallout of the destruction of the Global Financial Crisis of 2008, Tepper bet big on beaten-down banks like Bank of America ((BAC - Free Report) ) in 2009, buying them when no one wanted them for pennies and selling them for multi-bag gains, leading to a $7 billion annual windfall for his fund.

Image Source: Zacks Investment Research

In February, I wrote a piece titled "David Tepper’s Big Bets: China and AI" about Tepper’s newest, “all-in” high conviction bet: China. At the time, China had been recovering from one of the worst real estate collapses in history, a heavy-handed regulatory government, and a weak economy plagued with rampant inflation:

David Tepper’s Genius Lies in His Simplicity When I think of David Tepper’s success, I think of the quote “simplicity is the ultimate sophistication.” Unlike many prominent Wall Street firms, Tepper does not generate his returns through high-frequency trading or complex quant strategies. Instead, Tepper leverages a ‘first principles’ investing framework where he hyper-focuses on what might otherwise seem obvious to find high-probability, investment opportunities with asymmetric reward-to-risk.

Why Did David Tepper Buy Banks in 2009?David Tepper bought banks in 2009 for two simple, yet powerful reasons. Banks were criminally undervalued, and Tepper knew that the US government would not allow most major US banks to fail.

David Tepper’s “Buy Everything China Declaration”Fast-forward to February, and Tepper bought Chinese stocks for a similarly simple reason. Tepper realized that government officials in Beijing were intent on stimulating the market, saying, “When China wants to boost their stock market, the government will stop at nothing.” While it’s been a bumpy, headline-driven ride, the iShares China Large-Cap ETF ((FXI - Free Report) ) has gained a robust 35% year-to-date, again proving the power of straightforward thinking and high conviction bets.

Image Source: Zacks Investment Research

Can Chinese Stocks Continue to Run?Government Stimulus, De-regulation, Fast GrowthIn the most wide-ranging action since the global financial crisis, the Chinese government continues to implement stimulus measures, like interest rate cuts, fiscal stimulus, and support for the real estate market. Remember, liquidity is the single most critical market-moving factor, and China currently enjoys a plethora of it. Additionally, the Chinese government has become more lenient with business regulations. Meanwhile, China is growing rapidly, with the first-half 2025  GDP growth clocking in at a robust 5.3%.

Image Source: Arc Group, National Bureau of Statistics

Chinese Households have Excess Savings from Covid-19Stringent COVID-19 lockdowns and government-driven fear surrounding the virus have led to Chinese citizens saving a lot more money than most of the world. This excess savings should lead to a robust Chinese economy and a strong consumer.

Image Source: IMF, PT calculations, FT

AI: China Leads the Energy BattleAlthough Wall Street thinks of the United States as the leader in the red-hot AI industry, China is hot on its heels and is leading the AI race in some critical areas. One such area is energy. AI training requires hundreds of energy-hungry data centers. Without sufficient energy, the AI race is lost. From this perspective, China is leading the AI energy race significantly. In fact, China produces more than twice the energy that the United States produces, and this gap is expected to widen over time.

Image Source: Our World in Data

Meanwhile, in a recent interview on the “All in Podcast,” former Google CEO Eric Schmidt pointed out that China is focusing more of its AI efforts on practical applications of AI (which will produce revenue) instead of aiming for artificial general intelligence (AGI) like many of America’s big tech juggernauts.

China: Improving Fundamentals, EPS Estimates, & Inexpensive ValuationsWall Street analysts anticipate that Chinese companies such as Tencent Music ((TME - Free Report) ), Baidu ((BIDU - Free Report) ), and Nio ((NIO - Free Report) ) will generate robust earnings growth through 2026.

Image Source: Zacks Investment Research

Despite significant price advances in 2025, Chinese tech juggernauts like Alibaba ((BABA - Free Report) ) remain cheap.

Image Source: Zacks Investment Research

Bottom Line

David Tepper’s latest success with his China trade is a testament to his consistent, ‘first principles’ investment philosophy: bet against the crowd, focus on simple yet powerful fundamentals, and exude extreme conviction.

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has landed a new supply agreement with the University of Virginia Health, which is upgrading to complete the transition to full clinical Xenon MRI capabilities.

The deal provides additional equipment for clinical use, following UVA’s upgrade of two hyperpolariser systems last year.

UVA Health was the site of the first human scan using hyperpolarised Xenon MRI in 1996. The institution has since developed applications across asthma, cystic fibrosis and other lung diseases, and was recently awarded a $7.4 million NIH grant to advance research.

"We are delighted to support UVA Health as they prepare to launch their first clinical Xenon MRI scan, anticipated to occur later this year," said chief executive Christopher von Jako

"Their deep and sustained commitment to advancing pulmonary imaging - from early research breakthroughs to today's clinical transition - perfectly aligns with Polarean's mission to provide critical imaging solutions for chronic lung disease.

He added: "UVA Health's decades-long leadership in Xenon MRI has been instrumental in shaping the field, and we look forward to continuing our partnership to improve lung health for patients everywhere."

, /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced its unaudited financial results for the quarter ended June 30, 2025.

Highlights for the Quarter Ended June 30, 2025

Transaction volume was 11,606 units for the three months ended June 30, 2025, an increase of 40.4% from 8,264 units in the last quarter and an increase of 107.1% from 5,605 units in the same period last year.
Retail transaction volume was 10,385 units for the three months ended June 30, 2025, an increase of 37.6% from 7,545 units in the last quarter and an increase of 153.9% from 4,090 units in the same period last year.
Total revenues were RMB658.3 million (US$91.9 million) for the three months ended June 30, 2025, an increase of 30.6% from RMB504.2 million in the last quarter and an increase of 64.1% from RMB401.2 million in the same period last year.
Gross margin was 5.2% for the three months ended June 30, 2025, compared with 7.0% in the last quarter and 6.4% in the same period last year.
Loss from operations was RMB43.1 million (US$6.0 million) for the three months ended June 30, 2025, compared with RMB35.3 million in the last quarter and RMB62.5 million in the same period last year.
Non-GAAP adjusted EBITDA [1] was a loss of RMB16.5 million (US$2.3 million) for the three months ended June 30, 2025, compared with a loss of RMB8.9 million in the last quarter and a loss of RMB33.9 million in the same period last year.

[1] This is a non-GAAP measure. The Company believes that the non-GAAP measures help investors and users of our financial information understand the effect of adjusting items on our selected reported results and provide alternate measurements of its performance, both in the current period and across periods. See "Use of Non-GAAP Financial Measures" and "Unaudited Reconciliations of GAAP And Non-GAAP Results" contained in this press release for a reconciliation and additional information on non-GAAP measures.

Mr. Kun Dai, Founder, Chairman and Chief Executive Officer of Uxin, commented, "Our business sustained its strong growth momentum in the second quarter of 2025, with retail transaction volume reaching 10,385 units, representing a 154% year-over-year increase and marking the fifth consecutive quarter of growth above 140%. Importantly, we have also maintained healthy operating efficiency, with inventory turnover days stable at around 30, and customer satisfaction, as measured by NPS (net promoter score), at an industry-leading 65. Reflecting this strength, we now expect retail transaction volume growth of over 125% year-over-year in the third quarter. Accordingly, we are raising our full-year 2025 growth guidance to approximately 130% compared to calendar year 2024."

Mr. Dai continued, "Since opening in February, our Wuhan superstore has performed ahead of expectations, achieving monthly sales of about 1,400 units with steadily improving profitability. At the same time, the expansion of our new superstores is progressing on schedule, with our Zhengzhou superstore officially commencing operations on September 27. We believe that the continued ramp-up of newly launched superstores, together with the sales momentum at our existing locations, will serve as strong and sustainable growth drivers for our business performance in the years ahead."

Mr. Feng Lin, Chief Financial Officer of Uxin, stated, "Our strong sales growth this quarter was driven by improved inventory availability at existing stores and the continued ramp-up of our new superstore in Wuhan. Total revenues reached RMB658.3 million, including RMB607.6 million from retail vehicle sales, representing 87% year-over-year growth and 31% sequential growth. Our gross margin was 5.2%, reflecting the temporary impact of the new car price war in China, as well as the early-stage ramp-up of our Wuhan superstore. Looking ahead, we anticipate that unhealthy price competition in China's new car market will be largely resolved thanks to supportive government policies and sales and profitability of our Wuhan superstore will continue to improve. As a result, we anticipate a strong rebound in our overall gross margin in the near future. Specifically, for the third quarter of 2025, we expect retail transaction volume of 13,500 to 14,000 units, representing over 125% year-over-year growth, total revenues of between RMB830 million and RMB860 million, and gross margin recovery to approximately 7.5%."

Financial Results for the Quarter Ended June 30, 2025

Total revenues were RMB658.3 million (US$91.9 million) for the three months ended June 30, 2025, an increase of 30.6% from RMB504.2 million in the last quarter and an increase of 64.1% from RMB401.2 million in the same period last year. The increases were mainly due to the increase in retail vehicle sales revenue.

Retail vehicle sales revenue  was RMB607.6 million (US$84.8 million) for the three months ended June 30, 2025, representing an increase of 30.5% from RMB465.5 million in the last quarter and an increase of 87.0% from RMB325.0 million in the same period last year. For the three months ended June 30, 2025, retail transaction volume was 10,385 units, representing an increase of 37.6% from 7,545 units last quarter and an increase of 153.9% from 4,090 units in the same period last year. By offering quality products and services, the Company's superstores have earned customer trust and established Uxin as the well-recognized brand in regional markets, leading to a high in-store customer conversion rate. Additionally, since the Company's newly launched superstore in Wuhan commenced trial operations in February 2025, both its inventory levels and sales have increased rapidly.

Wholesale vehicle sales revenue was RMB29.9 million (US$4.2 million) for the three months ended June 30, 2025, compared with RMB22.5 million in the last quarter and RMB63.9 million in the same period last year. For the three months ended June 30, 2025, wholesale transaction volume was 1,221 units, representing an increase of 69.8% from 719 units last quarter and a decrease of 19.4% from 1,515 units in the same period last year. Wholesale vehicle sales represent vehicles purchased by the Company from individuals that do not meet the Company's retail standards and are subsequently sold through online and offline channels.

Other revenue was RMB20.8 million (US$2.9 million) for the three months ended June 30, 2025, compared with RMB16.2 million in the last quarter and RMB12.3 million in the same period last year.

Cost of revenues was RMB624.1 million (US$87.1 million) for the three months ended June 30, 2025, compared with RMB468.9 million in the last quarter and RMB375.6 million in the same period last year.

Gross margin was 5.2% for the three months ended June 30, 2025, compared with 7.0% in the last quarter and 6.4% in the same period last year. The quarter-over-quarter decrease in gross margin was mainly due to aggressive promotions in the new car sector in China during this quarter, which also put pressure on the gross margin for used cars. The year-over-year decrease in gross margin was mainly due to the trial operation of our new superstore in Wuhan, which commenced in February 2025. As the store is still in the early stage of operation, it is currently in a gross profit ramp-up phase. The Company expects that its overall gross margin will recover in the third quarter of 2025.

Total operating expenses were RMB96.7 million (US$13.5 million) for the three months ended June 30, 2025. Total operating expenses excluding the impact of share-based compensation were RMB86.8 million.

Sales and marketing expenses were RMB74.2 million (US$10.4 million) for the three months ended June 30, 2025, an increase of 20.3% from RMB61.7 million in the last quarter and an increase of 25.0% from RMB59.4 million in the same period last year. The increases were mainly due to the increased salaries for the sales teams.

General and administrative expenses were RMB19.4 million (US$2.7 million) for the three months ended June 30, 2025, representing an increase of 6.0% from RMB18.3 million in the last quarter and a decrease of 30.9% from RMB28.1 million in the same period last year. The year-over-year decrease was mainly due to the impact of share-based compensation expenses.

Research and development expenses were RMB3.1 million (US$0.4 million) for the three months ended June 30, 2025, representing an increase of 6.6% from RMB2.9 million in the last quarter and a decrease of 8.6% from RMB3.4 million in the same period last year.

Other operating income, net was RMB19.4 million (US$2.7 million) for the three months ended June 30, 2025, compared with RMB11.9 million for the last quarter and RMB2.8 million in the same period last year. The increases were mainly due to gains from derecognition of certain long-aged liabilities.

Loss from operations was RMB43.1 million (US$6.0 million) for the three months ended June 30, 2025, compared with RMB35.3 million in the last quarter and RMB62.5 million in the same period last year.

Interest expenses were RMB23.1 million (US$3.2 million) for the three months ended June 30, 2025, representing an increase of 2.5% from RMB22.5 million in the last quarter and an increase of 1.0% from RMB22.9 million in the same period last year.

Net loss from operations was net loss of RMB67.6 million (US$9.4 million) for the three months ended June 30, 2025, compared with net loss of RMB51.4 million in the last quarter and net loss of RMB49.8 million in the same period last year.

Non-GAAP adjusted EBITDA was a loss of RMB16.5 million (US$2.3 million) for the three months ended June 30, 2025, compared with a loss of RMB8.9 million in the last quarter and a loss of RMB33.9 million in the same period last year.

Liquidity

The Company has incurred net losses since inception. For the quarter ended June 30, 2025, the Company incurred net loss of RMB67.6 million and operating cash outflow of RMB131.8 million, and the Company's current liabilities exceeded current assets by approximately RMB202.2 million and the Company had accumulated deficit in the amount of RMB19.7 billion as of June 30, 2025. Based on the Company's liquidity assessment, which considers the management's plan to address these adverse conditions and events including growing its vehicle sales revenue by increasing the sales volume, improving the gross profit margin by increasing the value-added services offered to its customers, maintaining vehicle turnover rate by managing reasonable vehicle prices, raising funds from planned financings, and adjusting its operation scale if and when necessary, the Company believes that it is probable to effectively implement these plans and accordingly, its current cash and cash equivalents which included funds from  equity and debt financings and the cash flows from operations are sufficient for the Company to meet its anticipated working capital requirements and other capital commitments and the Company will be able to meet its payment obligations when liabilities that fall due within the next twelve months from the date of this release.

Recent Development

On September 27, 2025, Uxin officially opened its fourth used car superstore in Zhengzhou, Henan Province. The new facility spans approximately 150,000 square meters, can display up to 5,000 vehicles and integrates an advanced reconditioning factory. Situated in central China's key transportation hub, Zhengzhou provides strong market fundamentals with over 13 million residents and 5 million registered vehicles. The superstore's opening marks another successful replication of Uxin's large-scale superstore model and further strengthens the Company's market presence in central China.

Business Outlook

For the three months ended September 30, 2025, the Company expects its retail transaction volume to range between 13,500 units and 14,000 units. The Company estimates that its total revenues including retail vehicle sales revenue, wholesale vehicle sales revenue and other revenue to range between RMB830 million and RMB860 million. The Company expects its gross profit margin to be around 7.5%. These forecasts reflect the Company's current and preliminary views on the market and operational conditions, which are subject to changes.

Conference Call

Uxin's management team will host a conference call on Monday, September 29, 2025, at 8:00 A.M. U.S. Eastern Time (8:00 P.M. Beijing/Hong Kong time on the same day) to discuss the financial results. In advance of the conference call, all participants must use the following link to complete the online registration process. Upon registering, each participant will receive access details for this conference including an event passcode, a unique access PIN, dial-in numbers, and an e-mail with detailed instructions to join the conference call.

Conference Call Preregistration : https://dpregister.com/sreg/10203124/fff4e64580

A telephone replay of the call will be available after the conclusion of the conference call until October 6, 2025, 2025. The dial-in details for the replay are as follows:

U.S.:                   +1 877 344 7529
International:      +1 412 317 0088
Replay PIN:        8674929

A live webcast and archive of the conference call will be available on the Investor Relations section of Uxin's website at http://ir.xin.com.

About Uxin

Uxin is China's leading used car retailer, pioneering industry transformation with advanced production, new retail experiences, and digital empowerment. We offer high-quality and value-for-money vehicles as well as superior after-sales services through a reliable, one-stop, and hassle-free transaction experience. Under our omni-channel strategy, we are able to leverage our pioneering online platform to serve customers nationwide and establish market leadership in selected regions through offline superstores with inventory capacities ranging from 2,000 to 8,000 vehicles. Leveraging our extensive industry data and continuous technology innovation throughout more than ten years of operation, we have established strong used car management and operation capabilities. We are committed to upholding our customer-centric approach and driving the healthy development of China's used car industry.

Use of Non-GAAP Financial Measures

In evaluating the business, the Company considers and uses certain non-GAAP measures, including Adjusted EBITDA and adjusted net loss from operations per share – basic and diluted, as supplemental measures to review and assess its operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. The Company defines Adjusted EBITDA as EBITDA excluding share-based compensation, foreign exchange (losses)/gain, other income/(expenses), structure realignment cost which was mainly severance cost and equity in income of affiliates. The Company defines adjusted net loss attributable to ordinary shareholders per share – basic and diluted as net loss attributable to ordinary shareholders per share excluding impact of share-based compensation, deemed dividend to preferred shareholders due to triggering of a down round feature and accretion on redeemable non-controlling interests. The Company presents the non-GAAP financial measures because they are used by the management to evaluate the operating performance and formulate business plans. The Company also believes that the use of the non-GAAP measures facilitate investors' assessment of its operating performance as this measure excludes certain finance or non-cash items that the Company does not believe directly reflect its core operations. The Company believe that excluding these items enables us to evaluate our performance period-over-period more effectively and relative to our competitors.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using Adjusted EBITDA is that it does not reflect all items of income and expenses that affect the Company's operations. Share-based compensation, other income/(expenses) and foreign exchange (losses)/gain have been and may continue to be incurred in the business. Further, the non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.

The Company compensates for these limitations by reconciling the non-GAAP financial measure to the nearest U.S. GAAP performance measure, all of which should be considered when evaluating the Company's performance. The Company encourages you to review its financial information in its entirety and not rely on a single financial measure.

Reconciliations of Uxin's non-GAAP financial measures to the most comparable U.S. GAAP measure are included at the end of this press release.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars ("US$") at specified rates solely for the convenience of the reader, except for those transaction amounts that were actually settled in U.S. dollars. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB7.1636 to US$1.00, representing the index rate as of June 30, 2025 set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as Uxin's strategic and operational plans, contain forward-looking statements. Uxin may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Uxin's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Uxin's goal and strategies; its expansion plans; its future business development, financial condition and results of operations; Uxin's expectations regarding demand for, and market acceptance of, its products and services; its ability to provide differentiated and superior customer experience, maintain and enhance customer trust in its platform, and assess and mitigate various risks, including credit; its expectations regarding maintaining and expanding its relationships with business partners, including financing partners; trends and competition in China's used car e-commerce industry and other related industries; the laws and regulations relating to Uxin's industry; the general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Uxin's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Uxin does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media enquiries, please contact: 
Uxin Limited Investor Relations
Uxin Limited
Email: [email protected]

The Blueshirt Group
Mr. Jack Wang
Phone: +86 166-0115-0429
Email: [email protected]

Uxin Limited 

Unaudited Consolidated Statements of Comprehensive Loss

(In thousands except for number of shares and per share data)

For the three months ended  June 30,

For the six months ended  June 30,

2024

2025

2024

2025

RMB

RMB

US$

RMB

RMB

US$

Revenues

Retail vehicle sales

324,967

607,611

84,819

594,388

1,073,129

149,803

Wholesale vehicle sales

63,897

29,889

4,172

103,619

52,436

7,320

       Others

12,320

20,771

2,900

22,328

36,935

5,156

Total revenues

401,184

658,271

91,891

720,335

1,162,500

162,279

Cost of revenues

(375,599)

(624,064)

(87,116)

(673,708)

(1,092,952)

(152,570)

Gross profit

25,585

34,207

4,775

46,627

69,548

9,709

Operating expenses

Sales and marketing

(59,353)

(74,213)

(10,360)

(110,168)

(135,916)

(18,973)

General and administrative 

(28,119)

(19,443)

(2,714)

(103,455)

(37,777)

(5,273)

Research and development

(3,380)

(3,089)

(431)

(9,407)

(5,988)

(836)

Reversal of credit losses, net

-

19

3

359

414

58

Total operating expenses

(90,852)

(96,726)

(13,502)

(222,671)

(179,267)

(25,024)

Other operating income, net

2,783

19,379

2,705

3,718

31,327

4,373

Loss from operations

(62,484)

(43,140)

(6,022)

(172,326)

(78,392)

(10,942)

Interest income

16

43

6

24

50

7

Interest expenses

(22,858)

(23,098)

(3,224)

(46,828)

(45,640)

(6,371)

Other income

633

480

67

1,255

6,765

944

Other expenses

(800)

(1,498)

(209)

(4,886)

(2,153)

(301)

Net gain from extinguishment of debt

35,222

-

-

35,222

-

-

Foreign exchange gains/(losses) 

479

(353)

(49)

990

423

59

Loss before income tax expense

(49,792)

(67,566)

(9,431)

(186,549)

(118,947)

(16,604)

Income tax expense

(38)

(39)

(5)

(50)

(39)

(5)

Equity in loss of affiliates, net of tax   

-

-

-

(5,951)

-

-

Net loss, net of tax

(49,830)

(67,605)

(9,436)

(192,550)

(118,986)

(16,609)

Add: net profit attribute to redeemable non-controlling
interests and non-controlling interests shareholders

(1,641)

(6,192)

(864)

(3,270)

(7,882)

(1,100)

Net loss attributable to UXIN LIMITED

(51,471)

(73,797)

(10,300)

(195,820)

(126,868)

(17,709)

Deemed dividend to preferred shareholders due to
triggering of a down round feature

-

-

-

(1,781,454)

-

-

Net loss attributable to ordinary shareholders

(51,471)

(73,797)

(10,300)

(1,977,274)

(126,868)

(17,709)

Net loss

(49,830)

(67,605)

(9,436)

(192,550)

(118,986)

(16,609)

Foreign currency translation,  net of tax nil

(1,216)

16

2

(1,150)

91

13

Total comprehensive loss

(51,046)

(67,589)

(9,434)

(193,700)

(118,895)

(16,596)

Add: net profit attribute to redeemable non-controlling
interests and non-controlling interests shareholders

(1,641)

(6,192)

(864)

(3,270)

(7,882)

(1,100)

Total comprehensive loss attributable to UXIN LIMITED

(52,687)

(73,781)

(10,298)

(196,970)

(126,777)

(17,696)

Net loss attributable to ordinary shareholders

(51,471)

(73,797)

(10,300)

(1,977,274)

(126,868)

(17,709)

Weighted average shares outstanding – basic

56,412,679,304

63,168,535,224

63,168,535,224

30,439,110,903

60,735,577,407

60,735,577,407

Weighted average shares outstanding – diluted

56,412,679,304

63,168,535,224

63,168,535,224

30,439,110,903

60,735,577,407

60,735,577,407

Net loss per share for ordinary shareholders, basic

(0.00)

(0.00)

(0.00)

(0.06)

(0.00)

(0.00)

Net loss per share for ordinary shareholders, diluted

(0.00)

(0.00)

(0.00)

(0.06)

(0.00)

(0.00)

Uxin Limited

Unaudited Consolidated Balance Sheets 

(In thousands except for number of shares and per share data)

As of December 31,

As of June 30,

2024

2025

RMB

RMB

US$

ASSETS

Current assets

Cash and cash equivalents

25,112

68,267

9,530

Restricted cash

767

37

5

Accounts receivable, net

4,150

3,597

502

Loans recognized as a result of payments under
guarantees, net of provision for credit losses of
RMB7,710 and RMB7,706 as of December 31, 2024 and
June 30, 2025, respectively

-

-

-

Other receivables, net of provision for credit losses of
RMB21,113 and RMB15,149 as of December 31, 2024
and June 30, 2025, respectively

14,998

13,077

1,825

Inventory, net

207,390

279,446

39,009

Prepaid expenses and other current assets

86,977

83,087

11,599

Total current assets

339,394

447,511

62,470

Non-current assets

Property, equipment and software, net

71,420

75,499

10,539

Finance lease right-of-use assets, net

1,346,728

1,332,908

186,067

Operating lease right-of-use assets, net 

194,388

187,781

26,213

Total non-current assets

1,612,536

1,596,188

222,819

Total assets

1,951,930

2,043,699

285,289

LIABILITIES, MEZZANINE EQUITY AND
SHAREHOLDERS' DEFICIT

Current liabilities

Accounts payable

81,584

75,485

10,537

Other payables and other current liabilities

306,391

278,826

38,923

Current portion of operating lease liabilities

14,563

15,943

2,226

Current portion of finance lease liabilities

183,852

57,921

8,085

Short-term borrowings from third parties

174,616

221,582

30,932

Short-term borrowing from related parties

1,000

-

-

Total current liabilities

762,006

649,757

90,703

Non-current liabilities

Long-term borrowing from related party (i)

53,913

-

-

Long-term borrowing from third party

-

14,317

2,000

Consideration payable to WeBank

27,237

6,485

905

Finance lease liabilities

1,141,118

1,178,042

164,448

Operating lease liabilities

180,920

175,552

24,506

Total non-current liabilities

1,403,188

1,374,396

191,859

Total liabilities

2,165,194

2,024,153

282,562

Mezzanine equity

Redeemable non-controlling interests  (ii)

154,977

304,709

42,536

Total Mezzanine equity

154,977

304,709

42,536

Shareholders' deficit

Ordinary shares (iii)

39,816

43,733

6,105

Additional paid-in capital (iii)

19,007,948

19,213,990

2,682,169

Subscription receivable from shareholders

(60,467)

(60,467)

(8,441)

Accumulated other comprehensive income

227,718

227,809

31,801

Accumulated deficit

(19,583,017)

(19,709,885)

(2,751,395)

Total Uxin's shareholders' deficit

(368,002)

(284,820)

(39,761)

Non-controlling interests

(239)

(343)

(48)

Total shareholders' deficit

(368,241)

(285,163)

(39,809)

Total liabilities, mezzanine equity and shareholders'
deficit

1,951,930

2,043,699

285,289

(i) Long-term borrowing from related party outstanding as of December 31, 2024 amounted to RMB53.9 million. On September 12, 2024, the Company's
Anhui subsidiary ("Uxin Anhui") entered into a loan agreement with Pintu (Beijing) information Technology Co., Ltd. ("Pintu Beijing"), pursuant to
which Pintu Beijing agreed to extend loan to Uxin Anhui in a principal amount of the RMB equivalent of US$7.5 million for a term of 18 months from the
drawdown date unless other repayment schedule is negotiated and mutually agreed by Uxin Anhui and Pintu Beijing. The interest rate is 5.35% per
annum within 12 months after the drawdown date, and 8% per annum after 12 months until the loan is repaid in full. The loan is guaranteed by Uxin's
Shaanxi subsidiary pursuant to a guarantee agreement entered on the same date. On September 13, 2024, Uxin Anhui made the drawdown of this loan,
and the total RMB amount received was classified as "Long-term borrowings from related party" in non-current liabilities. Subsequently in November
2024, the Company entered into a Share Subscription Agreement with Lightwind Global Limited ("Lightwind", a wholly-owned subsidiary of Pintu
Beijing). Pursuant to this agreement and subject to the fulfilment of specified conditions, Uxin agreed to allot and issue, while Lightwind agreed to
subscribe for, a total of 1,543,845,204 Class A Ordinary Shares of the Company, with an aggregate subscription amount of US$7.5 million. When the
specified conditions were fulfilled and a repayment schedule of the long-term loan of US$7.5 million was mutually agreed, Lightwind shall invest
equivalent amount in the Company after Uxin Anhui repays the loan under the repayment schedule to Pintu Beijing.In March 2025, a revised repayment schedule was mutually agreed by Uxin Anhui and Pintu Beijing. Pursuant to which, Uxin Anhui fully repaid the total
amount of principal and interests, amounting to RMB55.0 million, to Pintu Beijing by 2 installments, RMB15.0 million in March 2025 and RMB40.0 million
in April 2025. Concurrently, Lightwind made an equivalent investment in the Company as the specified conditions for the investment had been fulfilled.

(ii) On October 16, 2024, the Company, through Uxin Anhui, entered into an agreement with Wuhan Junshan Urban Asset Operation Co.,Ltd. ("Wuhan
Junshan"), a company indirectly controlled by Wuhan City Economic & Technological Development Zone, to establish a subsidiary, Wuhan Youxin
Intelligent Remanufacturing Co., Ltd. ("Uxin Wuhan"). Uxin Anhui will contribute RMB66.7 million and Wuhan Junshan will contribute RMB33.3 million,
representing approximately 66.7% and 33.3% of Uxin Wuhan's total registered capital, respectively. As of June 30, 2025, the Company and Wuhan
Junshan each made contributions of RMB14.0 million to Uxin Wuhan, respectively, and the investment from Wuhan Junshan was recognized as
redeemable non-controlling interests.

On September 20, 2023, the Company entered into an equity investment agreement with Hefei Construction Investment. Pursuant to the agreement, Hefei
ConstructionInvestment will invest by multiple instalments in Uxin Hefei, and each instalment will be made after the lease payment is made by the Hefei
subsidiary, over a 10-yearperiod. As of June 30, 2025, the first-year and second-year rentals of approximately RMB147.1 million and RMB127.7 million
was converted intothe investment of approximately 12.02% and 8.40% equity interests in Uxin Hefei by Hefei Construction Investment, respectively. The
investment was recognized as redeemable non-controlling interests.

(iii) On March 4, 2025, the Company entered into a share subscription agreement with Fame Dragon Global Limited (the "Investor"), an investment
vehicle of NIO Capital, pursuant to which the Investor agreed to purchase 5,738,268,233 Class A Ordinary Shares of the Company for a total
consideration of US$27.8 million.  As of June 30, 2025, the Company had received US$19.0 million from Fame Dragon Global and issued 3,911,074,516
Class A Ordinary Shares of the Company to the Investor and entities designted by the Investor.

In substance, the Company issued a forward contract to the Investor, as the Investor is obligated to purchase the shares, and the Company is required
to issue them upon the satisfaction of the closing conditions at the pre-agreed price and amount which shall be a deemed dividend to the forward
contract holder recorded in the additional paid-in capital. In addition, given that this forward contract is considered indexed to the Company's own stock
and meet the requirement for equity classification, it was also classified under the Company's equity and was initially measured at fair value amounting to
RMB180.8 million with no subsequent remeasurement.

* Share-based compensation charges included are as follows:

For the three months ended June 30,

 For the six months ended June 30,

2024

2025

2024

2025

RMB

RMB

US$

RMB

RMB

US$

Sales and marketing

136

1,190

166

136

2,356

329

General and administrative

11,784

8,132

1,135

52,172

16,157

2,255

Research and development

128

625

87

128

1,242

173

Uxin Limited

Unaudited Reconciliations of GAAP And Non-GAAP Results 

(In thousands except for number of shares and per share data)

For the three months ended June 30,

 For the six months ended June 30,

2024

2025

2024

2025

RMB

RMB

US$

RMB

RMB

US$

Net loss, net of tax

(49,830)

(67,605)

(9,436)

(192,550)

(118,986)

(16,609)

Add: Income tax expense

38

39

5

50

39

5

Interest income

(16)

(43)

(6)

(24)

(50)

(7)

Interest expenses

22,858

23,098

3,224

46,828

45,640

6,371

Depreciation

16,577

16,649

2,324

32,337

33,242

4,640

EBITDA

(10,373)

(27,862)

(3,889)

(113,359)

(40,115)

(5,600)

Add: Share-based compensation expenses

12,048

9,947

1,388

52,436

19,755

2,757

- Sales and marketing

136

1,190

166

136

2,356

329

- General and administrative

11,784

8,132

1,135

52,172

16,157

2,255

- Research and development

128

625

87

128

1,242

173

Other income

(633)

(480)

(67)

(1,255)

(6,765)

(944)

Other expenses

800

1,498

209

4,886

2,153

301

Foreign exchange (gains)/losses

(479)

353

49

(990)

(423)

(59)

Structure realignment cost

-

-

-

13,948

-

-

Equity in loss of affiliates, net of tax

-

-

-

5,951

-

-

Net gain from extinguishment of debt

(35,222)

-

-

(35,222)

-

-

Non-GAAP adjusted EBITDA

(33,859)

(16,544)

(2,310)

(73,605)

(25,395)

(3,545)

For the three months ended June 30,

 For the six months ended June 30,

2024

2025

2024

2025

RMB

RMB

US$

RMB

RMB

US$

Net loss attributable to ordinary shareholders

(51,471)

(73,797)

(10,300)

(1,977,274)

(126,868)

(17,709)

Add: Share-based compensation expenses

12,048

9,947

1,388

52,436

19,755

2,757

- Sales and marketing

136

1,190

166

136

2,356

329

- General and administrative

11,784

8,132

1,135

52,172

16,157

2,255

- Research and development

128

625

87

128

1,242

173

Add: accretion on redeemable non-controlling
interests

1,650

6,298

879

3,300

7,986

1,115

Deemed dividend to preferred shareholders due to
triggering of a down round feature

-

-

-

1,781,454

-

-

Non-GAAP adjusted net loss attributable to ordinary
shareholders

(37,773)

(57,552)

(8,033)

(140,084)

(99,127)

(13,837)

Net loss per share for ordinary shareholders - basic

(0.00)

(0.00)

(0.00)

(0.06)

(0.00)

(0.00)

Net loss per share for ordinary shareholders -  
diluted

(0.00)

(0.00)

(0.00)

(0.06)

(0.00)

(0.00)

Non-GAAP adjusted net loss to ordinary
shareholders per share - basic and diluted

(0.00)

(0.00)

(0.00)

(0.00)

(0.00)

(0.00)

Weighted average shares outstanding - basic

56,412,679,304

63,168,535,224

63,168,535,224

30,439,110,903

60,735,577,407

60,735,577,407

Weighted average shares outstanding - diluted

56,412,679,304

63,168,535,224

63,168,535,224

30,439,110,903

60,735,577,407

60,735,577,407

Note: The conversion of Renminbi (RMB) into U.S. dollars (USD) is based on the certified exchange rate of USD1.00 = RMB7.1636 as of June 30, 2025 set forth in the H.10 statistical release of the Board of
Governors of the Federal Reserve System.

SOURCE Uxin Limited

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to provide an update on its proprietary Cladribine sublingual thin-film drug reformulation program (BNT23001), a next-generation delivery platform designed to improve bioavailability, patient adherence, and therapeutic outcomes in the treatment of neurological disorders, primarily multiple sclerosis (MS). Cladribine Sublingual Thin-Film Program: Manufacturing and Development Milestones BioNxt has successfully completed key technology transfers to its European contract development and manufacturing organization ("CDMO"), including both the process transfer and the analytical method transfer.

Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF) hailed a positive period of operational progress in the first half of 2025, as the portfolio of production assets saw drilling and development projects underway or planned for the near future, while the company remained debt-free.

Revenues of £1.29 million were generated, compared to £2.34 million a year ago, reflecting lower oil prices and a weaker US dollar.

Production averaged 149 barrels of oil equivalent per day, increasing to 164 boepd by the end of the period.

A net loss of £0.49 million was reported for the period, compared to a profit of £0.79 million a year earlier.

In Oklahoma, the Moccasin well was drilled and brought into production. A three-well drilling programme is underway, with testing in progress at the Sark well. 

Moccasin1-13 oil discovery, now in production, producing at a restricted gross 60+ barrels of oil per day.

Post-period, Union Jack raised £2 million through an institutional placing to fund the drilling activity.

In the UK, the Keddington oilfield resumed production after site upgrades. At Wressle, development and surface upgrades continue, aimed at enhancing production and eliminating routine flaring.

Executive chairman David Bramhill commented: "The half yearly results are operationally positive with the company remaining in a strong position, free of debt, retaining a robust balance sheet and holding a balanced portfolio of production assets on both sides of the Atlantic, complemented with numerous drilling and development projects that are either currently active or are planned for the near future."

He added that cash flows from 40%-owned Wressle and the 55%-owned Keddington, where production has recently been reinstated following site upgrades, are bolstering the balance sheet and are "contributing significantly to its financial well-being".

"At Wressle, the development programme is progressing, with preparation for new wells and gas monetisation which will enhance production and eliminate routine flaring. In parallel, the site's surface facilities are being upgraded to optimise current and future production efficiencies.

"West Newton, another key project within Union Jack's portfolio, retains the potential to surprise positively. Reabold Resources plc, the indirect majority holder of PED183, is working closely with the Company to extract the material value that we feel is present within the licence area.

"To date, our discovery success rate in the USA has been 100%. There will likely be some highs and lows in our quest for growth, however, I remain confident that our increased activity will accelerate progress and continue to support our growth ambitions going forward."

The £2 million raised in July are being used to conduct a three-well drilling programme in Oklahoma with drilling partners, Reach Oil & Gas.

"During the remainder of 2025, Union Jack will be involved in testing and completion of Sark, followed by drilling of the Crossroads and Wolverine wells in Oklahoma," he said.

"The company has a clear focus and the funding in place to complete its Oklahoma drilling programme.

"Meanwhile, in the UK, we are beginning to see some distinct signs of life in the supressed oil and gas sector and are keeping a watchful eye on wider industry developments as major international oil companies including BP return their focus to their 'grass roots'" E&P businesses.

"We are encouraged by this and will continue to pursue our own goals of production expansion and development at our key projects."

He concluded that "the future of Union Jack remains bright."

-

Find exceptional seasonal savings across top categories including up to 50% off select fashion from Levi’s and CIDER; up to 45% off select home products from BISSELL and iRobot; and up to 40% off select toys from American Girl, Play-Doh, and Tonies

Shop deals on new-to-Amazon brands like Vans, Milk Makeup, and Drunk Elephant; save on household essentials from brands like Dawn, Nespresso, and NEST New York; plus, Prime members can add a free grocery item like bananas, brownie bites, or baby carrots from a selection of favorites with eligible Same Day Delivery during Prime Big Deal Days

Come back and shop often with Today’s Big Deals—dropping three times a day and offering limited-time deals for Prime members like 70% off Amazon Echo Buds and 50% off or more on top brands like Keurig and STAUB. These offers are only available while supplies last

SEATTLE--(BUSINESS WIRE)--Amazon (NASDAQ: AMZN) is officially kicking off the holiday shopping season with Prime Big Deal Days, and Prime members can get exclusive access to shop millions of deals across popular categories—from beauty and electronics to must-have gifts and seasonal essentials. Beginning at 12:01 a.m. PT on October 7, members will find deals on kitchen and home products from top brands like KitchenAid and Shark, trending beauty products from brands like medicube and tarte, and thousands of toys under $20 including top toys from brands like Melissa & Doug and LEGO. Plus, stock up on household essentials from brands like Dove, Crest, and Dixie; and save on groceries with Campbell’s, Kellogg’s, and OREO. Members can prepare for the holidays with Halloween costumes, candy, and décor starting at $3, premium gifts starting at $20, and Christmas trees starting at $30—everything needed for memorable seasonal gatherings and holiday celebrations. Also, shop Amazon-Exclusive products in the Holiday Shop with deals from brands like National Tree Company, OPI, and Beats. Exciting new deals will continue to drop throughout the event, including Today’s Big Deals—special limited-time offers featuring some of the best savings of the season so far—dropping at 12 a.m., 8 a.m., and 1 p.m. PT from popular brands including Away, ELEMIS, and LG, available while supplies last. Want to join the excitement? Customers can unlock these exclusive savings by signing up for Prime membership and beginning a free trial at amazon.com/primebigdealdays.

“Prime Big Deal Days is all about giving our members a head start on the holidays—with millions of deals across popular categories like seasonal favorites, must-have gifts, and household essentials, all with the convenience of fast, free delivery. We’re working hard to provide low prices to help customers stock up and save on all items in one place, from groceries and home décor to electronics and toys to beauty and fashion,” said Carmen Nestares, vice president of North America Marketing and Prime Tech.

Preview Top Deals

Save up to 65% on select popular electronics from Anker like power banks and portable chargers

Save up to 50% on select Amazon devices including the Amazon Smart Plug and Echo Frames; and up to 45% on Amazon device bundles including the all-new Kindle Colorsoft Kids Essentials and Kindle Colorsoft Essentials bundles, Echo Show 5 Kids with Echo Glow, and the Ring Battery Doorbell Plus bundles

Save up to 50% on select apparel from Levi's and CIDER

Save up to 50% on select floorcare from Shark and eufy

Save up to 50% on select travel gear from Samsonite

Save up to 50% on select Zappos styles from brands including Crocs, Gola, and Steve Madden

Save up to 45% on select BISSELL and iRobot vacuums and mops

Save up to 45% on select Bose headphones and speakers

Save up to 40% on select Disney, Star Wars, and Wicked toys, apparel, and home goods

Save up to 40% on select toys from Fisher-Price, Ms. Rachel, Crayola, Play-Doh, NERF, and Tonies

Save up to 40% on select kitchen appliances from KitchenAid and Vitamix

Save up to 40% on select TVs and monitors from LG and Hisense

Save up to 40% on select apparel, footwear, and fashion from GAP, NAADAM, New Balance, and Swarovski

Save up to 40% on select makeup from tarte, Anastasia Beverly Hills, and IT Cosmetics

Save up to 35% on select denim; and up to 25% off select sweaters and outerwear for the whole family from Amazon Essentials

Save up to 30% on select home products from Dyson

Save up to 30% on select toys and building sets from LEGO, MAGNA-TILES, and PicassoTiles

Save up to 30% on select pet products from Blue Buffalo, Pet Honesty, and Zesty Paws

Save up to 30% on select premium beauty products from Estée Lauder, Lancôme, Shiseido, LANEIGE, URBAN DECAY, TULA, Dolce & Gabbana, Clinique, bareMinerals, Smashbox, and Too Faced

Save up to 30% on select skincare from ELEMIS, Kiehl’s, Dr.Jart+, and medicube

Save up to 30% on select haircare from VEGAMOUR, amika, Living Proof, Color Wow, and Aveda; and up to 25% on Dyson beauty products

Save up to 30% on select electronics from Sony and Samsung

Save up to 30% on select furniture, home, and décor styles from Ashley Furniture, Yankee Candle, WoodWick, and Eddie Bauer

Save up to 30% on select grocery essentials from Pepsi, Frito-Lay, and Dixie; and up to 20% on select products from CELSIUS and Liquid Death

Save up to 25% on select styles from Shopbop from brands including LE BOP, Madewell, Veja, and Lioness

Save up to 25% on select premium skincare from La Roche-Posay, Paula's Choice, and Youth to the People; and haircare from K18 and Nutrafol

Save up to 25% on select personal care and grooming items from Gillette, Braun, Dove, and Crest and household essentials from Dawn and Lysol

Save up to 20% on select haircare and makeup from Kitsch and Milk Makeup

Save up to 20% on select holiday items from National Tree Company, Fraser Hill Farm, and NEST New York

Save up to 20% on pre-loved designer handbags, jewelry, and accessories from What Goes Around Comes Around and Rebag

Save up to 20% on select beauty and skincare from Luxury Stores

Support Small Businesses

Prime members can kickstart their holiday shopping with exciting deals from small businesses selling in Amazon’s store during Prime Big Deal Days. Whether refreshing routines, updating wardrobes, or securing early holiday gifts, Prime members can discover and support small businesses that meet diverse shopping needs. Shoppers can find up to 55% off select skincare from TruSkin; 50% off select grooming products from The Beard Club and silk pillowcases from BLISSY; 40% off men’s fleece workout pants from PURE CHAMP and motivational cards from ED Design Concept; up to 30% off shower steamers from Body Restore, men’s essentials from True Classic, and modern area rugs from LUXE WEAVERS; 35% off leather conditioner from Leather Honey; 25% off Super C Serum from Vibriance Skin; and up to 20% off interactive sound books from Cali’s Books and protein powder blends from Sunwarrior. More than 60% of sales in Amazon’s store come from independent sellers—most of which are small- and medium-sized businesses—providing a vast selection of products, competitive prices, and great convenience for customers. Customers can discover and shop more small businesses in Amazon’s store all year long at amazon.com/supportsmall.

Access Prime Member Benefits

Prime Big Deal Days delivers additional value for members through entertainment offers, enhanced reward programs, and exclusive content at significant savings.

Add a Grocery Item to Same-Day Delivery Order: Prime members can select one free item from a selection of fresh groceries with their Same-Day Delivery order in eligible locations. Choose from a selection of perishable grocery items, including favorites like bananas, brownie bites, and baby carrots. This promotion is auto applied at checkout; terms apply. Prime members continue to enjoy year-round benefits with free Same-Day grocery delivery on orders of $25+ in eligible locations.

Earn more with Prime Visa and Prime Store Card: Prime members can get a $150 Amazon Gift Card instantly upon approval for Prime Visa, or a $100 Amazon Gift Card instantly upon approval for Prime Store Card (offer valid Oct. 2-8). Plus, cardmembers with an eligible Prime membership earn 10% back or more on select deals from brands like LEGO and Breville during the event with Prime Card Bonus and 5% back year-round at Amazon.com, Amazon Fresh, and Whole Foods Market (In-store code required for Prime Store Card), all with no annual credit card fees. As an extra perk, during the event members with Prime Visa or Prime Store Card can also earn an additional 2% back on eligible Amazon.com purchases with No-Rush Delivery (for a total of 7% back with an eligible Prime membership), subject to availability, and terms apply. See here for details.

Access Dining Benefits with Grubhub+: Prime members can use their free Grubhub+ membership ($120 annual value) to receive $10 off orders of $20 or more on Oct. 7-8 with code “DEALS10”. Prime members continue to enjoy year-round benefits including $0 delivery fees on eligible orders, reduced service fees, 5% credit back on pick-up orders, and exclusive offers. Additional fees and terms apply. Visit amazon.com/grubhub+ for details.

Boost Savings as a Young Adult: Prime for Young Adults members get exclusive 48-hour early access to shop Amazon-Exclusive products from brands like T3, Anua, and OCTOBUDDY—all with savings up to 30% off before the main event begins. Additionally, young adult members earn 10% cash back on these early access purchases and on all eligible beauty, apparel, electronics, and personal care purchases throughout the event. Eligible young adults ages 18-24 can join with a six-month $0 trial. Visit amazon.com/youngadult for details.

Shop In-Store at Amazon Fresh: Prime members can enjoy enhanced grocery savings with a monthly discount of $15 off purchases of $55+ when shopping in-store at Amazon Fresh. After Prime Big Deal Days, the regular monthly discount returns—$10 off purchases of $50+ for new Prime members and $10 off purchases of $100+ for returning Prime members. Terms apply. See here for details.

Discover Savings on Books: Prime members save up to 65% off thousands of bestselling print books including Cravings by Chrissy Teigen, Funny Story by Emily Henry, and The Great Alone by Kristin Hannah. Plus, members who prefer digital reading earn triple Kindle Points on all Kindle books purchased during the event—points can be redeemed for future Kindle book purchases.

Access Prime Video Savings: Prime members can enjoy savings on a selection of new and popular titles to rent or buy at up to 50% off, and access additional discounts on select subscriptions and bundles. See here for details.

Try Amazon Music Unlimited: Prime members who have not tried Amazon Music Unlimited can get four months free, for a limited time. Current Amazon Music Unlimited Individual customers can upgrade to a Family Plan at no extra cost for two months. Amazon Music Unlimited offers more than 100 million ad-free songs, and podcasts on-demand, and in high-quality streaming audio, plus the world’s largest collection of audiobooks from Audible, where you can enjoy one audiobook a month. See here for details.

Save on Healthcare: Prime members get $30 off their first year of One Medical membership, reducing the first-annual cost to just $69 (regularly $99 for Prime members). Enjoy 24/7 on-demand virtual care and prescription management. Insurance billed separately for scheduled visits. Prime members also get 50% off select One Medical Pay-Per-Visit message (where applicable) and video visits, with no insurance or membership required. Visit health.amazon.com/prime and health.amazon.com/onemedical/ppv for details.

Discover Ways to Shop

Prime Big Deal Days shopping becomes effortless with Amazon's suite of AI-powered tools that ease holiday shopping stress and help members discover the perfect gifts at the best prices.

Amazon’s AI shopping assistant Rufus offers seamless gift discovery, price alerts with optional automatic purchases, gift comparisons, personalized recommendations, and real-time answers to shopping questions.

Get price drop notifications with enhanced Alexa+ deal tracking that proactively monitors wish list, cart, or save for later items, sending ‘price drop’ notices when items you’re watching become deals.

Shop what you see anywhere with the Amazon Lens visual search tool enabling customers to quickly find similar products by taking a photo, and the new Lens Live feature that provides instant product matching in a swipeable format.

Explore product details by listening to Hear the Highlights, where AI shopping experts analyze product details, customer reviews, and web insights to create engaging audio conversations about items you're considering.

About Prime

Prime is savings, convenience, entertainment, and shopping innovation all in one membership. More than 200 million paid Prime members around the world enjoy access to Amazon’s enormous selection, exceptional value, and fast delivery. In the U.S., we offer more than 300 million items with free Prime shipping, including tens of millions of the most popular products available with Same Day or One-Day Delivery. Anyone can join Prime for $14.99 per month or $139 per year, or start a free 30-day trial if eligible at amazon.com/prime. Additionally, young adults can try Prime for Young Adults with a six-month $0 trial at amazon.com/youngadult, then pay a discounted rate of $7.49 per month or $69 per year for a membership. Qualifying government assistance recipients and income-verified customers can get Prime Access for $6.99 per month at amazon.com/getprimeaccess. For more information about Prime, including discounted memberships, visit aboutamazon.com/prime.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

More News From Amazon.com, Inc.

Back to Newsroom

COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion. The transaction has been unanimously approved by the Boards of Directors of both companies. A wholly owned subsidiary of Genmab (“Purchaser”) will commence a tender offer for 100% of Merus’ common shares, which is anticipated to close by early in the first quarter of 2026.

The proposed acquisition of Merus is expected to meaningfully accelerate Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained growth into the next decade and contributing to Genmab’s evolution into a biotechnology leader. The addition of petosemtamab, Merus’ lead asset, to Genmab’s promising late-stage pipeline is a compelling strategic fit with Genmab’s portfolio and aligns with Genmab’s expertise in antibody therapy development and commercialization in oncology. Following the closing of the transaction, Genmab will have four proprietary programs expected to drive multiple new drug launches by 2027.

“The proposed acquisition of Merus clearly aligns with our long-term strategy. It has the potential to significantly accelerate our evolution into a global biotechnology leader by providing durable growth for the company well into the next decade,” said Jan van de Winkel, Ph.D., President and Chief Executive Officer of Genmab. “Petosemtamab has the potential to be a transformational therapy for patients living with head and neck cancer. With our proven track record of success, both in clinical development and in commercialization, we are confident that we will be able to unlock the promise of petosemtamab.”

“We are excited for the opportunity to join Genmab, a leader in antibody therapeutics, to further develop and bring petosemtamab to patients. Our two companies have a rich history of innovation with multiple approvals in the field of multispecific antibodies. We believe Genmab has the right vision and experience to advance petosemtamab in recurrent/metastatic head and neck cancer and beyond,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “I’m immensely proud of the Merus team who have pioneered our foundational platform technologies to make better medicines and who have demonstrated - with an approved product and a product candidate, petosemtamab, in registrational studies - an ability to deliver on our promise to close in on cancer.”

Petosemtamab is an EGFRxLGR5 bispecific antibody with the potential to be both first- and best-in-class in head and neck cancer. It has been granted two Breakthrough Therapy Designations (BTD) by the U.S. Food and Drug Administration (FDA) for first- and second-line plus head and neck cancer indications. Of note, compelling Phase 2 data was presented at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting showing both an overall response rate and median progression free survival that were substantially higher than standard of care.

Merus is currently running two Phase 3 trials in first- and second/third line head and neck cancer, with topline interim readout of one or both trials anticipated in 2026. Based on Genmab’s experience in late-stage development and excellence in commercial execution, Genmab anticipates the potential for the initial launch of petosemtamab in 2027, subject to clinical results and regulatory approvals. Genmab also intends to broaden and accelerate petosemtamab’s development with potential expansion into earlier lines of therapy. Following its initial anticipated approval, Genmab believes that petosemtamab will be accretive to EBITDA with at least one-billion-dollar annual sales potential by 2029, with multi-billion-dollar annual revenue potential thereafter.

Details of the Transaction and Financing

Under the transaction agreement, Purchaser, a wholly owned subsidiary of Genmab, will commence a tender offer for all the outstanding common shares of Merus. Following the closing of the tender offer, Merus and Genmab will effect a series of transactions resulting in Genmab owning 100% of the common shares of Merus (or a successor entity). Depending on the structure of the back end transactions, Merus shareholders that do not tender their shares into the tender offer will either receive the same consideration for their common shares as the common shares tendered into the tender offer (subject to applicable withholding taxes) or a fair price for their common shares determined by a Dutch court in statutory buy-out proceedings. The closing of the tender offer is subject to the satisfaction of customary closing conditions for similar transactions, including a minimum acceptance condition of at least 80% of Merus’ common shares (which threshold may be reduced to 75% unilaterally by Genmab if all other closing conditions are satisfied), approval by Merus’ shareholders of resolutions relating to Merus’ post-closing governance and the back end transactions at Merus’ extraordinary shareholders meeting to be held for that purpose, and completion of the relevant works councils consultation processes.

The USD 97.00 per common share purchase price payable in the tender offer represents a premium of approximately 41% over Merus’ closing stock price on September 26, 2025, of USD 68.89 and approximately 44% over Merus’ 30-day volume weighted average price of USD 67.42.

The transaction is not subject to a financing condition. Consideration is expected to be funded through a combination of cash on hand and approximately $5.5 billion of non-convertible debt financing. Genmab has obtained a funding commitment from Morgan Stanley Senior Funding, Inc. for this amount.

The financing package includes a meaningful portion of prepayable debt, in line with Genmab’s commitment to deleveraging with a target of gross leverage <3x within two years after the closing of the proposed transaction. Today’s news does not impact Genmab’s financial guidance for the full year 2025, last issued on August 7, 2025. Genmab will provide its financial outlook for the full year 2026 in conjunction with its full year 2025 earnings report in February 2026.

PJT Partners and Morgan Stanley & Co. International plc are acting as joint financial advisors to Genmab and A&O Shearman and Kromann Reumert as its legal advisors.

Jefferies LLC is acting as financial advisor to Merus and Latham & Watkins and NautaDutilh as its legal advisors.

Conference Call Details

Genmab will hold a conference call to discuss the transaction today, September 29, 2025 at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT. To join the call please use the following registration link https://register-conf.media-server.com/register/BI65be2c038b9b42dbb064dfc843b6a478. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN. A live and archived webcast of the calls and relevant slides will be available at https://www.genmab.com/investor-relations.

About Genmab

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

About Merus

Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.

Additional Information

The tender offer for the common shares (“Common Shares”) of Merus referenced in this announcement has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell Common Shares or any other securities, nor is it a substitute for the tender offer materials that Genmab and Purchaser will file or cause to be filed with the Securities and Exchange Commission (the “SEC”) upon the commencement of the tender offer. This communication may be deemed to be solicitation material in respect of the EGM Proposals (defined below). At the time the tender offer is commenced, Genmab and Purchaser will file or cause to be filed with the SEC a tender offer statement on Schedule TO (the “Tender Offer Statement”), and Merus will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the “Solicitation/Recommendation Statement”), in each case, with respect to the tender offer. Merus also intends to file with the SEC a proxy statement on Schedule 14A in connection with an extraordinary general meeting of Merus’ shareholders, at which Merus’ shareholders will vote on certain proposed resolutions (the “EGM Proposals”) in connection with the transactions referenced herein, and will mail the definitive proxy statement and a proxy card to each shareholder of Merus entitled to vote at the extraordinary general meeting. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT AND THE PROXY STATEMENT WILL CONTAIN IMPORTANT INFORMATION. SHAREHOLDERS OF MERUS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF COMMON SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER OR MAKING ANY VOTING DECISION. The tender offer for Common Shares will be made only pursuant to the Offer to Purchase, the Letter of Transmittal and related documents filed as a part of the Tender Offer Statement. The Tender Offer Statement (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents), as well as the Solicitation/Recommendation Statement, will be made available to all holders of Common Shares at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Copies of the documents filed by Genmab or Purchaser with the SEC will also be available free of charge on Genmab’s website at https://www.genmab.com/investor-relations or by contacting Genmab’s investor relations department at [email protected]. Copies of the documents filed by Merus with the SEC will also be available free of charge on Merus’ website at https://ir.merus.nl/ or by contacting Merus’ investor relations department at [email protected]. In addition, shareholders of Merus may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender Offer Statement.

Participants in the Solicitation

Merus and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in soliciting proxies from its shareholders in connection with the proposed back end transactions. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of Merus’ shareholders in connection with the proposed back end transactions will be set forth in Merus’ definitive proxy statement for its extraordinary general meeting at which the EGM Proposals will be submitted for approval by Merus’ shareholders. You may also find additional information about Merus’ directors and executive officers in Merus’ Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 27, 2025 (as amended) and Merus’ Definitive Proxy Statement for its 2025 annual general meeting of shareholders, which was filed with the SEC on April 24, 2025.

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Statements in this Company Announcement that are forward looking may include, but are not limited to, statements regarding: the benefits and potential effects of the proposed transaction; the development plan, regulatory approval, data release timing, commercial launch timing and revenue potential of petosemtamab; the expected timing of the closing of the proposed transaction; and Genmab’s expectations regarding financing the proposed transaction, de-levering and timing of new drug launches. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, the occurrence of any event, change or other circumstance that could give rise to the right of Genmab or Merus or both of them to terminate the transaction agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the transaction agreement; the failure to obtain applicable regulatory approvals or clearances or Merus shareholder approval in a timely manner or otherwise; the risk that the proposed transaction may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the proposed transaction not being satisfied or waived; the risk that there may be unexpected costs, charges or expenses resulting from the proposed transaction; risks related to the ability of Genmab to successfully integrate Merus’ business with Genmab’s existing businesses and achieve the expected benefits of the proposed transaction within the expected timeframes or at all and the possibility that such integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction disrupts Genmab’s or Merus’ current plans and operations; risks related to disruption of each company’s management’s time and attention from ongoing business operations due to the proposed transaction; continued availability of capital and financing and rating agency actions; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Genmab’s and/or Merus’ securities or operating results; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Genmab and Merus to retain and hire key personnel, and to maintain relationships with their respective business partners and on their respective operating results and businesses generally; risks typically associated with conducting clinical trials, including the risk that additional clinical trials testing Merus’ products may not be successful; the risk that Merus’ products may not be approved on expected timelines or at all; the risk of litigation that could be instituted against Genmab or its directors, managers or officers and/or regulatory actions related to the proposed transaction, including the effects of any outcomes related thereto; risks related to unpredictable and severe or catastrophic events, including but not limited to acts of terrorism, war or hostilities, cyber-attacks, or the impact of any pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on Genmab’s and/or Merus’ business, financial condition and results of operations, as well the response thereto by each company’s management; and other business effects, including the effects of industry, market, economic, political or regulatory conditions. Also, actual results or performance of Genmab and Merus may differ materially from any future results or performance expressed or implied by such statements for a number of additional reasons as described in Genmab’s and Merus’ respective filings with the SEC, including those included in Genmab’s most recent Annual Report on Form 20-F, which is available at www.genmab.com and www.sec.gov, and those included in Merus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which is available at https://merus.nl/ and www.sec.gov. Neither Genmab nor Merus undertakes any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of DSP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

By Reuters

September 29, 20255:59 AM UTCUpdated ago

Item 1 of 2 Lufthansa planes stand parked in Frankfurt, Germany, March 7, 2024. REUTERS/Kai Pfaffenbach/File Photo

[1/2]Lufthansa planes stand parked in Frankfurt, Germany, March 7, 2024. REUTERS/Kai Pfaffenbach/File Photo Purchase Licensing Rights, opens new tab

Sept 29 (Reuters) - Lufthansa

(LHAG.DE), opens new tab will cut 4,000 administrative jobs by 20230 through digitalization, automation and process consolidation, the German airline said on Monday as part of its capital markets day.

The German company also set new mid-term targets for 2028 and 20230.

Sign up here.

It expects an adjusted earnings before interest and taxes margin of 8% to 10%, and its free cash flow is expected to generate over 2.5 billion euros per year.

Reporting by Ozan Ergenay and Tristan Veyet in Gdansk, editing by KIrsti Knolle

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Global science and technology company joins Swift pilot programme, leveraging Broadridge's API orchestration capabilities for on-demand account visibility across 400+ accounts

, /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE: BR), a global Fintech leader, today announced that Merck has selected Broadridge to implement Swift's new Instant Cash Reporting service through its Swift Service Bureau (SSB) and SCORE+ services. The comprehensive solution enables Merck to transform treasury operations with real-time, on-demand access to balance and transaction information of more than 400 accounts globally.

Broadridge's Swift Service Bureau is extensively proven to deliver fast-track access to the Swift network for the full range of financial messaging including payments, securities, derivatives and corporate actions, consistently delivering highly efficient financial transaction throughput, connectivity and proactive workflow control.

As part of Swift's Corporate Evolution initiative, Instant Cash Reporting marks a significant advancement from traditional next-day reporting. Developed through the Swift Corporate Working Group, where Broadridge serves as a key provider representative, this innovation builds on Broadridge's longstanding commitment to optimizing operations across the financial ecosystem — including its pioneering ISO 20022 migration services for corporates launched in 2007.

"Broadridge has been instrumental in addressing a fundamental challenge in our corporate treasury — the complexity and cost of implementing proprietary APIs across multiple banks," said Johann Lee, Principal Expert at Merck KGaA, Darmstadt, Germany. "Its SCORE+ platform and Swift Service Bureau will provide a single, standardized channel for real-time account data from our banking partners, which will enhance cash management and improve our payment processing experience."

Following the successful roll-out of payment tracking for inbound and outbound corporate payments, Instant Cash Reporting represents the second major capability delivered through Swift's Corporate Evolution initiative, all able to be harnessed via Broadridge's SSB and SCORE+ services.

"By enabling Merck to access real-time financial data across its extensive banking network, Broadridge is radically changing how global corporations manage their liquidity, and fundamentally enhancing operational efficiency," said Kai Marzenell, Director, Swift Product Management at Broadridge. "The combination of Broadridge's market leading scale and commitment to innovation technology enables us to transform financial operations for corporations across their range of global financial institution relationships."

Looking ahead, Broadridge is actively developing additional API-enabled services to further enhance the corporate payment experience. These forthcoming capabilities include Stop & Recall functionality and Payment Preparation tools, designed to create a comprehensive, end-to-end payment ecosystem that addresses the evolving needs of corporate treasurers across all channels.

Merck requires visibility across hundreds of accounts and anticipates making thousands of API calls annually, translating to roughly 900,000 intraday reports. Thanks to SCORE+, Merck can now retrieve information from up to 1,000 accounts in a single call, dramatically improving efficiency compared to traditional bank-by-bank API implementations.

Unlike traditional treasury management approaches that require multiple bank-specific API implementations, Broadridge's SSB and SCORE+ services simplify Swift integration while reducing implementation costs and complexity.

About Broadridge

Broadridge Financial Solutions (NYSE: BR) is a global technology leader with trusted expertise and transformative technology, helping clients and the financial services industry operate, innovate, and grow. We power investing, governance, and communications for our clients – driving operational resiliency, elevating business performance, and transforming investor experiences.

Our technology and operations platforms process and generate over 7 billion communications annually and underpin the daily average trading of over $15 trillion in equities, fixed income, and other securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 15,000 associates in 21 countries.

For more information about us, please visit www.broadridge.com

Media Contacts:

Europe
[email protected] 

North America
[email protected]

Asia-Pacific
[email protected]

SOURCE Broadridge Financial Solutions, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In